特发性肺纤维化与代谢失调的研究进展  

Research progress in idiopathic pulmonary fibrosis and metabolic dysregulation

作　　者：连娜琦 毛靖 姜淼[1] 鲁芯羽 赵凤鸣[1] 席蓓莉[1] 齐栩 李育[1] LIAN Na-qi;MAO Jing;JIANG Miao;LU Xin-yu;ZHAO Feng-ming;XI Bei-li;QI Xu;LI Yu(School of Medicine and Holistic Integrative Medicine,Nanjing University of Chinese Medicine,Nanjing 210023,China;Department of Respiratory Medicine,the First Affiliated Hospital of Nanjing Medical University/Jiangsu Provincial Hospi-tal,Nanjing 210029,China)

机构地区：[1]南京中医药大学医学院·整合医学学院,江苏南京210023 [2]南京医科大学第一附属医院/江苏省人民医院呼吸内科,江苏南京210029

出　　处：《中国病理生理杂志》2022年第5期949-953,共5页Chinese Journal of Pathophysiology

基　　金：江苏省卫生厅一般项目基金(No.H2019029);江苏省六个一项目(No.LGY2018054);“六大人才高峰”B级高级人才(No.WSN-015);333高级人才培养计划。

摘　　要：特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是一种病因不明的慢性间质性肺病(interstitial lung disease,ILD),该病在放射学和病理组织学上表现为间质性肺炎,并伴有实质纤维化和过度胶原沉积。IPF多发于65岁以上的吸烟者,常伴进行性呼吸困难和肺功能恶化,如不积极治疗,确诊后平均预期寿命仅有3~5年。随着全球人口老龄化,IPF对患者造成的生理、心理负担以及对社会造成的经济负担预计会稳步增加。抗纤维化药物(尼达尼布和吡非尼酮)能够延缓IPF的进展[1],但存在严重耐受性问题。肺移植是治愈IPF患者的唯一方法,不过出于年龄以及其他基础疾病等原因,该法仅适用于少数患者。亟需开发有效的IPF诊断监测方法以及新的IPF治疗药物。Idiopathic pulmonary fibrosis(IPF)is a chronic progressive lung disease.Metabolic dysregulation is involved in the pathogenesis of IPF,while its role in the pathogenesis of IPF has not been explored.In this paper,the proteomics research results of bronchoalveolar lavage fluid from patients with IPF in recent years were reviewed.The relationship between metabolic changes,especially the lipid metabolism,and the pathogenesis of IPF was emphasized.The metabolic changes of alveolar epithelial cells during the onset of IPF were summarized,which may provide a theoretical basis for the treatment of IPF.

关 键 词：特发性肺纤维化 代谢失调 蛋白质组学 肺泡Ⅱ型上皮细胞 

分 类 号：R363[医药卫生—病理学] R575[医药卫生—基础医学]